Vitality Biopharma Develops Cannabinoid Alternatives to Opiate Prescription Pain Medications

Cannabosides Enable Targeted Pain Relief and Avoid Psychoactivity of THC Through Site-Specific Delivery

ID: 1457774
recent pressrelease next pressrelease

(businesspress24) - LOS ANGELES, CA -- (Marketwired) -- 09/13/16 -- (OTCQB: VBIO) ("Vitality" or the "Company"), a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, wishes to advise that a written by Robert Brooke, Company CEO, sheds new light on key factors in the fight against the increasing epidemic of prescription painkiller related deaths.

In his article, Mr. Brooke notes, "Opiates are one of the key classes of drugs we''re seeking to replace, or to make far less necessary, as our proprietary cannabosides could provide a potent alternative form of pain relief and help avoid, or greatly reduce, the use of opiates for the treatment of many conditions including inflammatory bowel disease (where 70% of patients now regularly receive opiates upon hospitalization)."

The statistics are startling, as last year there were 47,055 Americans that died from drug overdoses, and opioids were involved in 61% of these cases. Since 2013, the rates of drug-overdose deaths have exceeded the number of deaths from car accidents. This is not uniquely an American problem, but the U.S. uses an astonishing 80% of the world''s opioids, while representing only 4.6% of the world''s population. The New England Journal of Medicine has just written that the rising death toll has been rivaled in modern history only by that at the peak of the AIDS epidemic in the early 1990s.

On Friday, the that an Arizona-based maker of fentanyl, the drug most commonly reported in many of these deaths, just donated $500,000 to oppose legalization of medical marijuana. This at a time when studies have shown that today about 75% to 86% of heroin users started with prescription opioid pain relievers. So the first exposure to opiates is far more likely to come not from heroin (as was overwhelmingly true in the 1960''s), but rather from prescription drugs.

To find out more about Vitality Biopharma and its development of cannaboside pharmaceuticals, please visit and to read Mr. Brooke''s article "What We Should Know About Opiates and Prescription Drug Abuse," please visit the CEO Blog at .

Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: . Follow us on , and .

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.


More information: http:// http://www.ecb

Keywords (optional):

stvf, vitality-biopharma, cannabinoids, neurological, inflammatory, epidemic, opiates, painkiller,

Company information / Profile:

PressRelease by


PressContact / Agency:

published by: Marketwired
print pressrelease  send to a friend  

Date: 09/13/2016 - 07:00
Language: English
News-ID 1457774
Character count: 2862
Firma: Vitality Biopharma, Inc.
Ansprechpartner: Feedback to about Pressrelease-id:


Number of hits: 99


Direct Link to this PressRelease:

We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease

All members: 9 438
Register today: 0
Register yesterday: 0
Members online: 0
Guests online: 63

Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.


[ more PressReleases ][ RSS-Feed ]